EUCTR2013-001775-20-SE进行中（未招募）1 期
A phase 2 study investigating the feasibility of using a topical formulation of lidocaine (SHACT) for hysteroscopy in women.
Pharmanest AB0 个研究点目标入组 10 人开始时间: 2013年5月7日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Patients planned for hysteroscopy under anaesthesia at Kvinnokliniken, Södersjukhuset
- •Has given written informed consent after verbal and written information
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 1
排除标准
- •Contraindication for hysteroscopy with lidocaine instillation at the discretion of the principal investigator
- •Known allergy to lidocaine
- •Recidivating porphyria
研究者
相似试验
尚未招募
不适用
A study investigating the feasibility of stereotactic radiotherapy for the palliation of Head and Neck CancerHead and Neck CancerCancer - Head and neckACTRN12621001548820South Western Sydney Local Health District40
尚未招募
2 期
Feasibility of ISRT after chemo-immmunotherapy in early nodal DLBCCTRI/2018/03/012340All India Institute of Medical Sciences
招募中
2 期
Phase II study on the feasibility and efficacy of consolidation with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory aggressive B-cell non-Hodgkin*s lymphoma having achieved partial or complete remission after induction with R-PECC chemotherapy.Aggressive B-cell NHL10025320lymphomaNL-OMON36830HOVO60
进行中（未招募）
不适用
Phase II study on the feasibility and efficacy of R-DHAP + HD-MTX, combined with intrathecal rituximab, followed by autologous stem cell transplantation in patients with a recurrent aggressive B-cell lymphoma with CNS localisation - HOVON 80 NHrelapsed B cell lymphomaMedDRA version: 8.1Level: LLTClassification code 10029547Term: Non-Hodgkin's lymphomaEUCTR2006-002141-37-NLHOVON foundation35
进行中（未招募）
不适用
Phase II study on the feasibility and efficacy of consolidation with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma having achieved partial or complete remission after induction with R-PECC chemotherapy.Aggressive B-cell NHLMedDRA version: 14.1Level: PTClassification code 10003902Term: B-cell lymphoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10003903Term: B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2006-007083-28-NLHOVON foundation60